Abstract PS5-02-02: Early use of CDK4/6 inhibitor combined with endocrine therapy plus anti-HER2 antibody may get more survival benefit in HR+/HER2+ advanced breast cancer: result from a phase II single-arm mini cohort study (CABC016)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: Y. Liu, S. Guohong, R. Ran, J. Hanfang, S. Bin, X. Liang, Z. Jiayang, Z. Ruyan, L. Huiping
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129200687
Cites:
Cited by:
Related to: